Lonza Potelligent CHOK1SV host cell line
Potelligent CHOK1SV, a host cell line for manufacturing recombinant antibodies, combines BioWa’s glycosylation Potelligent technology with Lonza’s GS Gene Expression System and CHOK1SV.
The cell line retains the features of a high-productivity cell line (robust, high-yielding, scalable) and the bioprocess platform for CHOK1SV is repeatable in the new cell line.
Antibodies produced by the new cell line: exhibit enhanced antibody dependent cellular cytotoxicity (ADCC) even with the low-ADCC allotype of CD16, overcoming CD16 polymorphism; can exert potent cytotoxic effects when their target antigen is low; work in whole blood; and retain required features of antibodies, such as Protein A binding.
Phone: 1300 657508
Amsbio validated cytokines for organoid culture
Amsbio has launched over a range of over 30 independently developed and manufactured organoid...
Dendritics monoclonal antibodies for dendritic cell research
Dendritics' mouse and rat antibodies are logically grouped into several product families: DC...
Bioss In Vivo Biosimilar Antibodies
Bioss In Vivo Biosimilar Antibodies are research-grade copies of therapeutic antibodies that are...
